TH45345B - Poultry vaccine That has a formulation of polynucleotides - Google Patents

Abstract

DC60 (03/11/54) A avian vaccine formulation containing at least three valencies of polynucleotide vaccines, each valency incorporating plasmic molecules containing genes for expression in live host cells encoding one valency of an avian pathogen. These valencies are selected from a group containing avian Marek's disease virus, Newcastle disease virus, Bursal disease virus, bronchitis virus, and anemia virus. The plasmic molecules for each valency include one or more genes selected from the group: gB and gD for Marek's disease virus, HN and F for Newcastle disease virus, VP2 for Bursal disease virus, S, M, and N for bronchitis virus, and C+NS1 for anemia virus. A vaccine formulation for poultry must contain at least three valencies of vaccine polynucleotides, each containing a plasmid containing genes (designed for expression in living host cells) encoding one valency of an avian pathogen. These valencies are selected from a group including avian Marek's disease virus, Newcastle disease virus, bursal disease virus, bronchitis virus, and anemia virus. The plasmid (for each valency) contains one or more genes selected from a group including gB and gD for Marek's disease virus, HN and F for Newcastle disease virus, VP2 for bursal disease virus, S, M, and N for bronchitis virus, and C+NS1 for anemia virus. (Figure 2)

Claims (14)

1. The vaccine formulation for poultry consists of at least three valence vaccine polynucleotides, each containing a plasmid containing genes incorporated (which are capable of expression in living host cells) with one avian pathogen valence. These valences are selected from groups containing Marek's disease virus, Newcastle disease virus, and Anemia virus. The plasmid contains (for each valence) one or more genes selected from groups containing gB and gD for Marek's disease virus, HN and F for Newcastle disease virus, VP2 for Bursal disease virus, and C+NS1 for Anemia virus. 2. A vaccine formulated according to claim 1 herein for a Marek's disease valence consisting of gene gB alone. 3. A vaccine formulated according to claim 1, containing the HN and F genes of the Newcastle disease virus, which are in the same or different plasmids. 4. A vaccine formulated according to claim 1, where the plasmid for the anemia virus contains C+NS1 in the same plasmid. 5. A vaccine formulated according to any of the claims 1 through 4, containing at least one valency selected from a group comprising bronchitis viruses, laryngitis and pharyngitis viruses, meningitis and encephalitis viruses, pneumonia viruses, and avian plague viruses; a plasmid containing (for these valencies) one or more genes selected from a group comprising genes S, M, and N for bronchitis viruses, gB and RD for laryngitis and pharyngitis viruses, env and gag/pro for meningitis and encephalitis viruses, F and G for pneumonia viruses, and HA, N, and NP for avian plague viruses. 6. A vaccine formulated according to claim 5 herein for a viral valence causing bronchitis consisting of gene S alone. 7. A vaccine formulated according to claim 5 herein for the viral valence causing laryngitis containing gene gB alone. 8. Vaccines formulated according to claim 5 herein for the pneumococcal valence virus, consisting of 2 genes, F and G, on different plasmids or on the same plasmid. 9. A vaccine formulated according to claim 5 herein for the valency of the avian plague virus where the formula contains only the HN gene. 10. A vaccine formulated according to claim 5 herein for the viral encephalitis valency, which includes the env gene 11. A vaccine formulation conforming to any of the claims 1 through 10, containing 10 nanograms to 1 milligram, where the required dose is from 100 nanograms to 500 micrograms, and even more required is from 0.1 micrograms to 50 micrograms of each plasmid. 12. The use of one or more plasmids as described in any of the claims 1 through 11 for the manufacture of vaccines for poultry with the intention of administering a first dose to animals. This first dose vaccine shall be selected from a pool consisting of viable cell vaccines, attenuated cell vaccines, subunit vaccines, recombinant vaccines, and shall contain plasmid-encoded antigens or cross-protective antigens. 13. A vaccination kit supplied with any of the formulations in Reputations 1 through 11 and selected avian vaccines from a group comprising whole-cell vaccines, attenuated whole-cell vaccines, recombinant vaccine subunits, first-dose vaccines containing polynucleotide-encoded antigens, or cross-protective antigens, for subsequent administration or as a booster in combination with the aforementioned formulations. 14. A vaccine formulated according to any of the claims in Claims 1 through 11, provided in accompanying documentation demonstrating that this vaccine formulation can be used as a booster for the first vaccination of selected poultry from a pool comprising whole-cell vaccines, attenuated whole-cell vaccines, vaccine subunits, recombinant vaccines, vaccines administered for the first vaccination containing an antigen encoded by the vaccine polynucleotide, or an antigen that produces cross-protective effects (Claims 14, page 3, figure 26).